Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Strategies and Reimbursement

Set Alert for Pricing Strategies

What’s Next? Five Things To Look Out For In December

Generics Bulletin previews the most noteworthy and anticipated events for December 2023.

Generic Drugs Biosimilars

Dr Reddy’s Aghanian Highlights European Opportunities

Dr Reddy’s sees plenty of opportunity in Europe, including for the firm’s burgeoning biosimilars business. However at the same time, current European pricing policies risk exacerbating shortages and are discouraging investment, the firm’s CEO of European operations for global generics, Patrick Aghanian, tells Generics Bulletin in an exclusive interview.

Strategy Europe

Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention

Office of Inspector General analysis could add momentum to reforms of the rebating system.

Reimbursement Biosimilars

BGMA Hits Out At UK’s New Voluntary Pricing Scheme

A fresh UK voluntary pricing scheme for branded medicines has been unveiled that includes differentiated payment mechanisms for older and newer products. However, the BGMA has hit out against aspects of the new deal that it says will provide hurdles for generics and increase the risk of drug shortages.

United Kingdom Regulation

Lamotrigine Leads October Increases In UK

Four presentations of epilepsy treatment lamotrigine topped WaveData’s table of the fastest-rising prices of typical generics in the UK in October.

Market Intelligence Pricing Strategies

Cencora Biosimilars Chiefs Talk Adalimumab Pricing, Interchangeability And The IRA

With several Humira biosimilars entering the US market, price competition was fiercer and faster than expected in the second half of 2023, according to Cencora. The former AmerisourceBergen firm’s biosimilars experts Brian Biehn and Connor Nell touch on topics including adalimumab trends, ophthalmology and oncology biosimilars, and the Inflation Reduction Act in a Q&A with Generics Bulletin.

Biosimilars United States

European Opportunities Loom For Value Added Medicines

Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in early November. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.

Value-Added Medicines Europe

PBM Reform Bill Reducing Cost Sharing In Part D Clears Senate Panel Without Biosimilar Policies

Finance Committee is hoping to attach pharmacy benefit manager reform legislation to end-of-year budget legislation but the prospect is unpredictable at this point.

Reimbursement Policy

UK’s ‘Pioneering’ Medicines Repurposing Program Delivers First License

Now that the first license for a drug has been obtained in partnership with the program, work will begin to ensure other companies that make the product adopt the new licensed indication.

Value-Added Medicines United Kingdom

Part D Cost Sharing Based On Net Price, Boost For ‘High Discount’ Biosimilars Proposed In Draft Bill

Senate Finance Committee’s PBM legislation would essentially pass through rebate value at the pharmacy counter for some drugs, block situations where beneficiaries pay more than plans and reward biosimilars that have list prices substantially below their reference products.

Reimbursement Policy

Rasagiline Rise Outstrips Other UK Increases In September

With large treble-digit-percentage generic price rises scarce in the UK in September, a recently-launched molecule – rasagiline – showed the steepest increase, according to the latest information from market researcher WaveData.

Market Intelligence Pricing Strategies

FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab

An FDA decision around the timing of first interchangeable biosimilar exclusivity has brought to an end Boehringer Ingelheim’s time on the market with a unique interchangeable Humira rival, with the agency also granting interchangeability for Pfizer’s Abrilada version of adalimumab.

Biosimilars Regulation

Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.

Reimbursement Medicare

Boehringer Accelerates Adalimumab Dual Pricing Strategy With 81% Discount

Boehringer Ingelheim says it is pushing ahead with an earlier than expected launch of a deep-discounted unbranded version of its Cyltezo adalimumab biosimilar in the US, as it looks to compete with other Humira rivals.

Biosimilars Pricing Strategies

Generics Savings Once Again Could Help A Major US Health Care Reform Bill

A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.

Legislation Reimbursement

Betahistine Leads A Raft Of UK Rises In August

With multiple generic molecules experiencing treble-digit-percentage price increases in the UK in August, betahistine tablets led the month’s biggest risers, according to WaveData.

Market Intelligence Pricing Strategies